About one in five U.S. adults experiences major depression during their lifetime. Although most patients respond to antidepressants or psychotherapy, nearly one-third develop treatment-resistant depression (TRD), a debilitating condition that persists despite multiple therapies. Now, new evidence suggests that vagus nerve stimulation (VNS) may provide sustained relief for even the most severe cases.
A Landmark Trial in Treatment-Resistant Depression
Researchers at Washington University School of Medicine in St. Louis led a large, multicenter clinical trial evaluating VNS in patients with long-standing, severe TRD. Participants had lived with depression for an average of 29 years and had failed a mean of 13 prior treatments, including electroconvulsive therapy and transcranial magnetic stimulation. The findings, from the ongoing RECOVER trial, were published in the International Journal of Neuropsychopharmacology.
How Vagus Nerve Stimulation Works
VNS involves implanting a small device under the skin of the chest. The device delivers carefully calibrated electrical impulses to the left vagus nerve, a key communication pathway between the brain and vital organs. Researchers designed the RECOVER study to assess whether adding VNS to existing treatments could improve depressive symptoms, quality of life, and daily functioning over time.
Sustained Benefits Over Two Years
As reported by medicalxpress, the trial enrolled nearly 500 patients across 84 U.S. sites. During the first year, only half of the implanted devices were activated. Earlier results showed that patients with active stimulation experienced longer periods of symptom improvement and better functioning. In the latest two-year analysis, nearly 69% of patients receiving active treatment showed meaningful improvement at one year.
Importantly, more than 80% of these responders maintained or enhanced their benefits at two years. Moreover, 92% of those with substantial improvement at one year continued to benefit after two years. Notably, nearly one-third of patients who initially showed no response improved during the second year.
A Promising Path Forward
After 24 months, more than 20% of treated patients achieved full remission, regaining normal daily functioning. According to lead investigator Dr. Charles Conway, these durable results are rare in severe TRD. Overall, the findings suggest that VNS can help patients not only get better, but stay better, offering renewed hope for those with few remaining options.